Sensei Biotherapeutics, Inc. (SNSE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Sensei Biotherapeutics reported revenue of $0. Net income was -$21.1M, or -$16.72 per diluted share. Operating activities generated -$20.5M of cash, leaving -$20.5M of free cash flow. At fiscal year end, Sensei Biotherapeutics held $22.9M in total assets against $4.3M in total liabilities, including $8.7M of cash and equivalents.
Open the full interactive Sensei Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Sensei Biotherapeutics Key Stats
| Share Price | $21.51 |
|---|---|
| Market Cap | $121.4M |
| 52-Week Range | $7.89 – $40.05 |
| Shares Outstanding | 5.6 million (basic, 2026 Q2) |
Sensei Biotherapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$37.5M | -$50.2M | -$37.1M | -$32.6M | -$22.3M |
| Pre-Tax Income | -$36.8M | -$48.6M | -$34.1M | -$30.2M | -$21.1M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$36.8M | -$48.6M | -$34.1M | -$30.2M | -$21.1M |
| Diluted EPS | -$26.60 | -$31.60 | -$24.40 | -$24.00 | -$16.72 |
Sensei Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.6M | -$4.7M | -$170.2M | -$16.0M |
| Diluted EPS | -$3.62 | -$3.74 | -$131.45 | -$2.84 |
Sensei Biotherapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $7.2M | $17.8M | $13.0M | $10.0M | $8.7M |
| Current Assets | $148.5M | $108.6M | $67.2M | $41.9M | $21.5M |
| Total Assets | $153.2M | $118.4M | $74.4M | $45.4M | $22.9M |
| Current Liabilities | $4.9M | $9.1M | $5.6M | $5.4M | $4.3M |
| Total Liabilities | $6.7M | $15.0M | $9.5M | $7.0M | $4.3M |
| Shareholders' Equity | $146.5M | $103.4M | $64.9M | $38.4M | $18.6M |
Sensei Biotherapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$30.3M | -$39.0M | -$32.0M | -$24.7M | -$20.5M |
| Cash From Investing | -$143.1M | $49.9M | $38.4M | $22.4M | $19.8M |
| Cash From Financing | $163.9M | -$287,000 | -$11.2M | -$787,000 | -$645,000 |
| Free Cash Flow | -$32.3M | -$39.3M | -$32.2M | -$24.8M | -$20.5M |
Figures from Sensei Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sensei Biotherapeutics financials page for every line item.
Sensei Biotherapeutics Company Profile
| Ticker | SNSE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Austin, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001829802 |
Frequently Asked Questions
What was Sensei Biotherapeutics' revenue in fiscal 2025?
Sensei Biotherapeutics (SNSE) reported revenue of $0 for fiscal 2025.
What is Sensei Biotherapeutics' annual revenue history?
Sensei Biotherapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Sensei Biotherapeutics' net income in fiscal 2025?
Sensei Biotherapeutics reported net income of -$21.1M for fiscal 2025.
What was Sensei Biotherapeutics' earnings per share (EPS) in fiscal 2025?
Sensei Biotherapeutics' diluted EPS was -$16.72 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Sensei Biotherapeutics generate in fiscal 2025?
Sensei Biotherapeutics generated -$20.5M of free cash flow in fiscal 2025.
What was Sensei Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Sensei Biotherapeutics reported revenue of $0.
How many shares of Sensei Biotherapeutics are outstanding?
Sensei Biotherapeutics reported a weighted average of 5.6 million basic shares outstanding in 2026 Q2.
What is Sensei Biotherapeutics' market cap?
Based on its latest closing price, Sensei Biotherapeutics (SNSE) has a market capitalization of about $121.4M.
When does Sensei Biotherapeutics' fiscal year end?
Sensei Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Sensei Biotherapeutics headquartered?
Sensei Biotherapeutics lists its business address in Austin, Texas in its SEC filings.